CAR-T Commercialization Lessons: Insights from the Yescarta Launch

Following last month's In Vivo podcast, the conversation continues in a newly published article, What Industry Can Learn From The CAR-T Commercialization Playbook, featuring Litmys Managing Partner Harris Kaplan, alongside Diane Parks and Jim Haag.

Expanding on their discussion of the Yescarta launch, the article explores why breakthrough therapies require more than strong clinical data to achieve commercial success. From reimbursement and referral pathways to operational complexity and health system readiness, the discussion highlights the factors that ultimately determine whether innovation is adopted in the real world.

While the lessons stem from CAR-T, the implications extend across the life sciences industry: approval may open the door, but adoption is what determines commercial success.

Read the full article to see what every launch team can learn from one of the industry's most influential commercialization stories.